Oncolytics reports positive preclinical data for pelareorep with RAS inhibitors

Oncolytics Biotech announced initial preclinical findings showing pelareorep demonstrated greater anti-tumor activity in combination with RAS-targeted approaches compared to individual treatments in solid tumor models. The company plans additional studies in pancreatic and colorectal cancer models with full results expected in late 2026, potentially supporting a combination strategy for RAS-mutated cancers.